Results 241 to 250 of about 735,101 (274)

Is stereotactic radiosurgery of brain metastases in patients with poor performance status worthwhile?

Journal of Clinical Oncology, 2017
192 Background: Performance status is a consistent predictor of outcome in people with advanced disease. Variable prognosis has not led to the exclusion of patients with Karnofsky performance scores of < 70 from treatment of brain metastases (BRM) with stereotactic radiosurgery (SRS).
Federico Ampil, Donghyun Kim, Troy Richards, Moiz Vora, Glenn Morris Mills, Anil Nanda   +5 more
openaire   +2 more sources

Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status?

Journal of Clinical Oncology, 2013
534 Background: The management of patients with poor performance status (PS) remains challenging in the absence of data on optimal treatment. Here we assessed the treatment and outcomes of patients with metastatic colorectal cancer (mCRC) with poor Eastern Cooperative Oncology Group (ECOG) PS (≥ 2) in routine clinical care.
Hui-li Wong, Kathryn M Field, Jeanne Tie, Suzanne Kosmider, Jeremy David Shapiro, Joseph McKendrick, Phillip Parente, Lara Rachel Lipton, Desmond Yip, Sagun Parakh, Louise M. Nott, Peter Gibbs   +11 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Stereotactic Radiosurgery for Poor Performance Status Patients

International Journal of Radiation Oncology*Biology*Physics, 2016
Patients with poor performance status (PS), usually defined as a Karnofsky Performance Status of 60 or less, were not eligible for randomized stereotactic radiosurgery (SRS) studies, and many guidelines suggest that whole-brain radiation therapy (WBRT) is the most appropriate treatment for poor PS patients.In this retrospective review of our SRS ...
Gregory J, Kubicek, Alan, Turtz, Jinyu, Xue, Ashish, Patel, Gregory, Richards, Tamara, LaCouture, Louis, Cappelli, Tim, Diestelkamp, Piya, Saraiya, Anne, Bexon, Nati, Lerman, Howard Warren, Goldman   +11 more
openaire   +2 more sources

Efficacy of sequential radiation and chemotherapy in treating glioblastoma with poor performance status

Journal of Neuro-Oncology, 2020
While the current standard of care after maximal safe resection for glioblastoma (GBM) is concomitant radiation and chemotherapy, the ideal therapy for patients with poor performance status remains in question due to concerns about treatment tolerance.
Elsa Parr, Richard L. Sleightholm, Michael J. Baine, Nicole A. Shonka, Tony J. Wang, Chi Zhang   +5 more
openaire   +2 more sources

Prolongation of Survival and Improvement in Performance Status following Palliative Chemotherapy in Gastrointestinal Cancer Patients with a Poor Performance Status

Oncology, 2008
<i>Background:</i> The prognosis of advanced gastrointestinal cancer, especially in patients with poor performance status (PS), is generally dismal. Patients with PS 3–4 are almost ineligible for participation in clinical studies. <i>Patients and Methods:</i> From June 2000 to February 2007, 116 patients with poor PS (PS 3 = 73 ...
Kohei, Shitara, Masaki, Munakata, Masaharu, Kasai, Osamu, Muto, Yuh, Sakata   +4 more
openaire   +2 more sources

Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC

Lung Cancer, 2002
Increasing interest in designing chemotherapy suitable for use in the elderly and in poor performance status (PS) patients has led to clinical trials in advanced non-small cell lung cancer (NSCLC) which have demonstrated a number of important points.
Cesare, Gridelli, John, Hainsworth
openaire   +2 more sources

Treatment of Patients with Advanced Lung Cancer and Poor Performance Status

Clinical Lung Cancer, 2004
Patients with advanced lung cancer and poor performance status (PS) have been underrepresented in clinical trials. As a consequence, the management of these patients in clinical practice is empirical and inconsistent. Recent data in advanced non-small-cell lung cancer (NSCLC) indicate that patients with a PS of 2 tend to benefit from first-line ...
openaire   +2 more sources

[Role of Palliative Care in the Introduction of Chemotherapy in Patients with Poor Performance Status].

Gan to kagaku ryoho. Cancer & chemotherapy, 2021
Chemotherapy for patients with poor performance status(PS)is not recommended because it increases the risk of death and shortens their survival. We report on 3 cases in which palliative care improved PS and enabled chemotherapy, resulting in a prolonged prognosis.
Itaru, Sato, Naoki, Nakaya, Yoko, Obara, Natsumi, Kurosaka, Souichirou, Ueno, Hideo, Nakajima   +5 more
openaire   +2 more sources

Initiation of Chemotherapy in Cancer Patients with Poor Performance Status: A Population-Based Analysis

Journal of Palliative Care, 2014
Objective: Practice guidelines indicate that patients who have months to weeks left to live should not be offered chemotherapy. We examined factors associated with clinician-reported poor performance status as determined by the Palliative Performance Scale (PPS) and subsequent initiation of intravenous (IV ...
Joan, Porter, Craig, Earle, Clare, Atzema, Ying, Liu, Doris, Howell, Hsien, Seow, Rinku, Sutradhar, Deborah, Dudgeon, Amna, Husain, Jonathan, Sussman, Lisa, Barbera   +10 more
openaire   +2 more sources

[A clinical review of pleurodesis for patients with poor performance status].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2012
Although pleurodesis is an effective treatment for malignant pleural effusion, we hesitate to use in patients with poor performance status (PS) because of its side effects.Of 46 pleurodesis cases in our institution between 2006 and 2010, 24 poor PS cases (>3) were classified into 2 groups according to survival (beyond 3 months) or non-survival, and 3 ...
Katsutoshi, Ando, Yoshihiro, Ohkuni, Hideki, Makino, Akina, Komatsu, Ryo, Matsunuma, Kei, Nakashima, Nobuhiro, Asai, Norihiro, Kaneko   +7 more
openaire   +1 more source